Welcome to our dedicated page for Ibio news (Ticker: IBIO), a resource for investors and traders seeking the latest updates and insights on Ibio stock.
iBio, Inc. develops AI-driven precision antibody therapies for cardiometabolic, obesity and cardiopulmonary diseases. Company news commonly covers pipeline updates for IBIO-600, a long-acting anti-myostatin monoclonal antibody, and IBIO-610, an Activin E antibody candidate, along with preclinical body-composition data and regulatory clearances tied to early clinical development.
Recurring updates also include iBio's antibody-discovery approach, including computational biology and epitope-steering, as well as financial results, capital financing, investor-conference presentations and board or committee changes.
iBio (NASDAQ:IBIO) reported Q3 FY2026 results and a broad pipeline update. The company received Australian regulatory and ethics clearance to start a first-in-human Phase 1 trial of obesity candidate IBIO-600, with initial dosing in overweight and obese adults expected in Q2 calendar 2026.
iBio expanded its pipeline into PH-HFpEF with a selective bispecific antibody and reported new obese NHP data for IBIO-610, showing 6.7% visceral fat and 5.2% total fat mass reductions in a small, non-powered study. Q3 revenue was zero; R&D rose to $3.3M and G&A to $5.1M, including a $2.5M IBIO-101 impairment. Cash, equivalents and debt securities were $74.8M at March 31, 2026, plus $17M gross from Q4 FY2026 warrant exercises, extending the cash runway into Q4 FY2028.
iBio (NASDAQ:IBIO) appointed Elizabeth Stoner, M.D., M.S., to its Board of Directors and to the Compensation Committee on May 8, 2026, concurrent with the departure of director Eef Schimmelpennink.
Dr. Stoner brings over 35 years of R&D leadership, industry and board experience and will support iBio as it begins its first human clinical trial for IBIO-610, IBIO-600 and other assets.
iBio (NASDAQ: IBIO) received Clinical Trial Notification acknowledgement from Australia’s TGA and Human Research Ethics Committee approval to start a Phase 1 first-in-human study of IBIO-600. The randomized, double-blind, placebo-controlled single ascending dose trial targets overweight and obese adults.
First participant dosing is expected in 2Q 2026. IBIO-600 targets myostatin and GDF11 to preserve lean mass, is engineered for infrequent dosing (potentially 2–4 times per year) and showed a 40–52 day half-life and up to 5.1% lean-mass gains in non-human primates, with accompanying fat-mass reductions in preclinical studies.
iBio (NASDAQ:IBIO) will host a corporate update call on March 17, 2026 at 4:00 p.m. ET to discuss expansion into pulmonary hypertension associated with HFpEF (PH-HFpEF) and its engineered selective bispecific antibody program.
iBio expects to select an optimized bispecific development candidate in Q3 2026 before starting IND-enabling activities.
iBio (NASDAQ: IBIO) reported preclinical body composition data for IBIO-610 in obese non-human primates showing a 6.7% reduction in visceral fat and a 5.2% reduction in total fat mass after two once-every-eight-week doses, with a slight uptick in lean mass.
iBio also reported an extended 33.2-day half-life in obese NHPs and a projected human half-life up to 100 days, supporting potential twice-yearly dosing; full dataset and additional biomarker analyses will be presented at scientific conferences in 2026.
iBio (NASDAQ: IBIO) announced executive participation in two investor conferences: a virtual fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026 at 2:00 p.m. ET, and a fireside chat at the Leerink Global Healthcare Conference on Monday, March 9, 2026 at 4:20 p.m. ET in Miami.
Martin Brenner, DVM, Ph.D., CEO and CSO, and Felipe Duran, CFO, will present and be available for one-on-one meetings; livestreams and replays will be accessible via the investor site for 90 days.
iBio (NASDAQ:IBIO) reported Q2 FY2026 results and a corporate update on Feb 10, 2026. The company closed a $26 million PIPE financing led by Frazier Life Sciences and received net proceeds of ~$24.4 million, extending cash runway into Q3 FY2028. Cash, cash equivalents and debt investments totaled $52.7 million as of Dec 31, 2025.
Preclinical progress includes NHP data for IBIO-610 (predicted human half-life up to 100 days), IBIO-600 toxicology nearing completion with Phase 1a planned in H1 2026, and ongoing CMC/toxicology to support IBIO-610 human trials in early 2027.
iBio (NASDAQ:IBIO) announced a private placement expected to raise approximately $26 million gross, led by Frazier Life Sciences with participation from existing healthcare-focused institutional investors. The offering is expected to close on or about January 13, 2026, subject to customary conditions. iBio will sell 11,061,738 shares of common stock (or pre-funded warrants) at $2.35 per share (or $2.349 per pre-funded warrant). Proceeds are intended to advance preclinical cardiometabolic programs including IBIO-610, IBIO-600, and myostatin/activin A bispecific programs, and to fund other pipeline work and working capital. The financing extends iBio’s cash runway into calendar 2028. The securities were offered to accredited investors in a Regulation D/Section 4(a)(2) placement; iBio agreed to file registration statements covering resale.
iBio (NASDAQ: IBIO) will participate in the 8th Annual Evercore Healthcare Conference in Miami, December 2–4, 2025. Martin Brenner, DVM, Ph.D., CEO and Chief Scientific Officer, will appear in a fireside chat on Thursday, December 4, 2025 at 8:45 a.m. ET to discuss iBio’s progression of its next‑generation obesity pipeline toward clinical development and recent non‑human primate data for IBIO‑610 presented at ObesityWeek 2025.
Felipe Duran, CFO, will be available for one‑on‑one meetings during the conference. A livestream will be available and a replay link will be posted on the company’s Investor website.
iBio (NASDAQ:IBIO) reported Q1 fiscal 2026 results and a corporate update on Nov 12, 2025. Key highlights include a closed $50.0M underwritten public offering of pre-funded warrants and common warrants with up to $100.0M potential gross proceeds if common warrants are fully exercised, and cash, cash equivalents and debt investments of $49.6M as of Sept 30, 2025, which the company says supports operations into the fourth quarter of fiscal 2027.
iBio presented non-human primate data for IBIO-610 showing a predicted human half-life up to 100 days, consistent with dosing as infrequent as twice per year, and preclinical evidence of fat-selective, GLP-1–synergistic weight-loss and sustained weight maintenance.